Shah Nimish P — SEC Form 4 filings
SEC reporting owner CIK 1698082. 20 Form 4 filings on record with FilingPulse; latest filed 2026-09-10.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-01-10 to 2026-09-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 32 legs across 12 filings — 1,156,725 shares, $13,656,248 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 1 filing — 214,631 shares, $3,691,148 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: sale of 174,485 shares @ $16.95 ($2,957,521) in KalVista Pharmaceuticals, Inc., filed 2026-03-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Inc. (KALV) | 10% owner | 13 | 27 legs · 1,033,843 sh · $12,248,880 | 5 legs · 214,631 sh · $3,691,148 | 1 |
| Oruka Therapeutics, Inc. (ORKA) | 10% owner | 1 | 5 legs · 122,882 sh · $1,407,368 | — | — |
| Apogee Therapeutics, Inc. (APGE) | Director | 5 | — | — | 11 |
| Korsana Biosciences, Inc. (KRSA) | Director | 1 | — | — | 1 |
Form 4 filings — Shah Nimish P
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-10 | 4 | Korsana Biosciences, Inc. (KRSA) | Grant/award (A): 48,445 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Apogee Therapeutics, Inc. (APGE) | Disposition to issuer (D): 1,750,000 @ $135.11 · Disposition to issuer (D): 6,743,321 (derivative) @ $135.11 · Disposition to issuer (D): 47,758 (derivative) · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) · +1 more | EDGAR |
| 2026-06-11 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Koh Bong Y | Sale (S): 174,485 @ $16.95 · Sale (S): 160 @ $17.53 · Sale (S): 21,386 @ $17.76 · Sale (S): 15,417 @ $18.82 · Sale (S): 3,183 @ $19.12 | EDGAR |
| 2025-10-15 | 4 | Apogee Therapeutics, Inc. (APGE) | Purchase (P): 365,853 (derivative) @ $41.00 | EDGAR |
| 2025-06-20 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 14,461 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Koh Bong Y | Purchase (P): 25,000 @ $9.42 | EDGAR |
| 2025-02-27 | 4 | Oruka Therapeutics, Inc. (ORKA) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Koh Bong Y | Purchase (P): 574 @ $10.90 · Purchase (P): 9,593 @ $10.95 · Purchase (P): 8,971 @ $11.86 · Purchase (P): 14,950 @ $11.63 · Purchase (P): 88,794 @ $11.44 | EDGAR |
| 2025-02-14 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Koh Bong Y | Purchase (P): 100,000 @ $9.23 · Purchase (P): 61,700 @ $9.33 | EDGAR |
| 2025-02-11 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Koh Bong Y | Purchase (P): 73,649 @ $9.29 · Purchase (P): 4,137 @ $9.14 · Purchase (P): 26,703 @ $9.18 | EDGAR |
| 2025-02-03 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Koh Bong Y | Purchase (P): 43,707 @ $8.76 · Purchase (P): 11,754 @ $8.89 · Purchase (P): 14,562 @ $9.22 | EDGAR |
| 2024-06-07 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 10,370 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., Koh Bong Y, VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P. | Purchase (P): 655,738 (derivative) @ $15.25 | EDGAR |
| 2024-02-08 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., Koh Bong Y, VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P. | Purchase (P): 4,474 @ $14.74 · Purchase (P): 51,827 @ $14.56 · Purchase (P): 29,747 @ $14.70 | EDGAR |
| 2024-02-01 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., Koh Bong Y, VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P. | Purchase (P): 88,099 @ $14.47 | EDGAR |
| 2024-01-29 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., Koh Bong Y, VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P. | Purchase (P): 7,030 @ $12.73 · Purchase (P): 4,174 @ $12.98 · Purchase (P): 80,600 @ $14.22 | EDGAR |
| 2024-01-24 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., Koh Bong Y, VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P. | Purchase (P): 67,546 @ $12.55 · Purchase (P): 10,897 @ $12.54 · Purchase (P): 20,686 @ $12.44 | EDGAR |
| 2024-01-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Koh Bong Y | Purchase (P): 78,925 @ $12.60 · Purchase (P): 39,680 @ $12.51 · Purchase (P): 25,000 @ $12.43 | EDGAR |
| 2024-01-16 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Koh Bong Y | Purchase (P): 6,647 @ $12.68 · Purchase (P): 19,599 @ $12.73 | EDGAR |
| 2024-01-10 | 4 | KalVista Pharmaceuticals, Inc. (KALV) jointly with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Koh Bong Y | Purchase (P): 69,184 @ $12.44 · Purchase (P): 20,816 @ $12.56 · Purchase (P): 47,700 @ $12.67 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-10 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1698082 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →